Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Lung Neoplasms 1

Interventions

Cetuximab 5Erlotinib Hydrochloride 3Radiotherapy 2Radiation 2Everolimus 2Docetaxel 2Cisplatin 2talactoferrin alfa 1mercaptoundecahydrododecaborate 1VTX-2337 1Taxes 1Sunitinib 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Pharmacogenomic Testing 1Microarray Analysis 1Lenalidomide 1Immunohistochemistry 1Hydroxyurea 1Gene Expression Profiling 1Fluorouracil 1Electrophoresis, Polyacrylamide Gel 1Chemotherapy, Adjuvant 1Carboplatin 1CBLB502 1Biopsy 1Albumin-Bound Paclitaxel 14-boronophenylalanine-fructose 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Tongue Neoplasms × talactoferrin alfa × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡